SAN DIEGO, CA — Kite, a Gilead Company, announced compelling new data at the major ASH 2025 hematology conference today, reinforcing the value of its CAR T-cell therapy, Yescarta$^circledR$, for patients battling aggressive blood cancer.
The new analysis pooled results from two key studies, ZUMA-7 and ALYCANTE, providing a comprehensive look at Yescarta’s performance in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have few options left—including those who cannot undergo standard high-dose chemotherapy and transplant.
Key Findings After Two Years:
The pooled data showed a substantial advantage for patients treated with Yescarta, achieving an Overall Survival (OS) rate of 64.9%—a dramatic improvement compared to historical survival rates of approximately 20% for this patient group.
Other strong indicators of success include:
Progression-Free Survival: 47.4%
Sustained Response: 61% of responders maintained their response at 12 months.
Crucially, the treatment showed a consistent and manageable safety profile across all patient groups analyzed. Furthermore, the data showed that after a short initial period, patients reported marked and sustained improvements in their quality of life lasting up to two years.
Kite leadership commented that the combined data strongly support Yescarta’s potential as a treatment with curative intent for this difficult-to-treat cancer.